MedTrace Logo

Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM

NCT06447727 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-06-07

No results posted yet for this study

Summary

To observe the PFS of yttrium \[90Y\] microsphere injection combined with FOLFIRI and bevacizumab in second-line treatment of CRLM.

Conditions

  • Colorectal Cancer Metastatic

Interventions

DRUG

SIRT with Yttrium-90 Microspheres

Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection

DRUG

FOLFIRI and Bevacizumab

FOLFIRI and Bevacizumab

Sponsors & Collaborators

  • Zhongda Hospital

    lead OTHER

Principal Investigators

  • Gao-Jun Teng · Zhongda Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2025-11-30
Completion
2025-11-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06447727 on ClinicalTrials.gov